Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis

Annals of Oncology

Volumn 20, Issue 2, 2009, Pages 231-238

  Bollschweiler, Elfriede ^a   Metzger, R ^a   Drebber, U ^a   Baldus, S ^b   Vallbohmer D ^a   Kocher, M ^a   Holscher A H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Adenocarcinoma squamous cell carcinoma; Esophageal cancer; Lymph node metastases; Neo adjuvant chemoradiation; Prognosis

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 60549115069     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn622     Document Type: Article

References (44)

1. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: Role of surgery and other modalities. Lancet Oncol 2007; 8: 545-553.
2. Urschel J, Vasan H, Blewett C. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002; 183: 274-279.
3. Kaklamanos I, Walker G, Ferry K et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: A meta-analysis of randomized clinical trials. Ann Surg Oncol 2003; 10: 754-761.
4. Urschel J, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-543.
5. Fiorica F, Di BD, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis. Gut 2004; 53: 925-930.
6. Greer S, Goodney P, Sutton J, Birkmeyer J. Neoadjuvant chemoradiotherapy for esophageal carcinoma: A meta-analysis. Surgery 2005; 137: 172-177.
7. Kelsen D, Winter K, Gunderson L et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007; 25(24): 3719-3725.
8. Fietkau R. Definitive and neoadjuvant radiochemotherapy of squamous cell carcinoma of the oesophagus. Onkologie 2004; 27: 39-44.
9. Bonavina L, Soligo D, Quirici N et al. Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia. Surgery 2001; 129: 15-22.
10. O'Sullivan GC, Sheehan D, Clarke A et al. Micrometastases in esophagogastric cancer: High detection rate in resected rib segments. Gastroenterology 1999; 116: 543-548.
11. Lordick F. Neoadjuvante Therapie des Magen- und Ösophaguskarzinoms. J Onkol 2006; 3: 7-10.
12. Walsh TN, Noonan N, Hollywood D et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-467.
13. Gebski V, Burmeister B, Smithers B et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234.
14. Cunningham D, Allum W, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
15. Macdonald J, Samlley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
16. Sobin LH, Wittekind C (eds): TNM classification of malignant tumors, 6th edition. New York: John Wiley & Sons 2002.
17. Hölscher A, Schroder W, Bollschweiler E et al. How safe is high intrathoracic esophagogastrostomy? Chirurg 2003; 74: 726-733.
18. Hölscher A, Bollschweiler E, Bumm R et al. Prognostic factors of resected adenocarcinoma of the esophagus. Surgery 1995; 118: 845-855.
19. Holscher AH, Schroder W, Gutschow C, Schneider PM. Laparoscopic ischemic conditioning of the stomach for esophageal replacement. Ann Surg 2007; 245: 241-246.
20. Bollschweiler E, Schroder W, Holscher A, Siewert J. Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the oesophagus. Br J Surg 2000; 87: 1106-1110.
21. Schroder W, Bollschweiler E, Kossow C, Holscher A. Preoperative risk analysis-a reliable predictor of postoperative outcome after transthoracic esophagectomy? Langenbecks Arch Surg 2006; 391: 455-460.
22. Schneider P, Baldus S, Metzger R et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: Implications for response classification. Ann Surg 2005; 242: 684-692.
23. Wijnhoven B, Tran K, Esterman A et al. An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg 2007; 245: 717-725.
24. Baldus S, Monig S, Schroder W et al. Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: Criteria of the histopathological evaluation. Pathologe 2004; 25: 421-427.
25. Bollschweiler E. Benefits and limitations of Kaplan-Meier calculations of survival chance in cancer surgery. Langenbecks Arch Surg 2003; 388: 239-244.
26. Kaplan EL. Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Asoc 1958; 53: 457-481.
27. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: Good practice and pitfalls. Lancet 2002; 359(9318): 1686-1689.
28. Samel S, Hofheinz R, Hundt A et al. Neoadjuvant radio-chemotherapy of adenocarcinoma of the oesophagogastric junction. Onkologie 2001; 24: 278-282.
29. Geh J, Bond S, Bentzen S, Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006; 78: 236-244.
30. MacGuill M, Mulligan E, Ravi N et al. Clinicopathologic factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer. Dis Esophagus 2006; 19: 273-276.
31. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
32. Junker K, Thomas M, Schulmann K et al. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy: Histological assessment. J Cancer Res Clin Oncol 1997; 123: 469-477.
33. Becker K, Mueller JD, Schumacher C et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98: 1521-1530.
34. Shimosato Y, Oboshi S, Baba K. Histological evaluation of the effects of radiotherapy and chemotherapy for carcinomas. Jpn J Clin Oncol 1971; 1: 19-35.
35. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer 1994; 73: 2680-2686.
36. Prenzel K, Konig A, Schneider P et al. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. Ann Surg Oncol 2007; 14: 954-959.
37. Wu T, Chirieac L, Abraham S et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: A reliable predictor for patient outcome. Am J Surg Pathol 2007; 31: 58-64.
38. Chang E, Smith C, Corless C et al. Accuracy of pathologic examination in detection of complete response after chemoradiation for esophageal cancer. Am J Surg 2007; 193(5): 614-617; discussion 617.
39. Hölscher A, Bollschweiler E, Schneider P, Siewert J. Early adenocarcinoma in Barrett's oesophagus. Br J Surg 1997; 84: 1470-1473.
40. Peyre C, Demeester S, Rizzetto C et al. Vagal-sparing esophagectomy: The ideal operation for intramucosal adenocarcinoma and Barrett with high-grade dysplasia. Ann Surg 2007; 246: 665-674.
41. Sato Y, Motoyama S, Maruyama K et al. A second malignancy is the major cause of death among thoracic squamous cell esophageal cancer patients negative for lymph node involvement. J Am Coll Surg 2005; 201: 188-193.
42. Matsubara T, Yamada K, Nakagawa A. Risk of second primary malignancy after esophagectomy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003; 21: 4336-4341.
43. Hölscher A, Bollschweiler E, Schneider P, Siewert J. Prognosis of early esophageal cancer. Comparison between adeno- and squamous cell carcinoma. Cancer 1995; 76: 178-186.
44. Rouvelas I, Zeng W, Lindblad M et al. Survival after neoadjuvant therapy compared with surgery alone for resectable esophageal cancer in a population-based study. World J Surg 2006; 30: 2182-90; discussion 2191-2192.